# BPL-003

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/bpl-003
Canonical HTML page: https://gethealthbrief.com/entity/bpl-003

## Timeline

- **2026-06-01**: Phase 3 Initiation — Expected launch of the global Phase 3 program for BPL-003 in TRD.
- **2026-03-08**: Results Announcement — Company reports 2025 results and confirms Phase 3 timeline.
- **2025-12-31**: Fiscal Year End — AtaiBeckley completes 2025 with focused R&D spending on lead assets.
- **2024-01-01**: Strategic Investment — atai Life Sciences invests $50M in Beckley Psytech to accelerate BPL-003.

## Recent coverage (1 stories)

### AtaiBeckley Confirms Q2 2026 Phase 3 Launch for BPL-003 Following 2025 Results
2026-03-08 18:25:52 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

AtaiBeckley has announced its 2025 financial results, highlighted by the upcoming Q2 2026 Phase 3 trial launch for its lead candidate, BPL-003. The intranasal 5-MeO-DMT compound is positioned as a potential blockbuster for treatment-resistant depression with a significantly shorter clinical footprint than existing therapies.
Full story: https://gethealthbrief.com/story/ataibeckley-2025-results-bpl-003-phase-3-launch

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.